Stockreport

DSMB recommends continuation of BioCardia's cell therapy trial for heart failure [Yahoo! Finance]

BioCardia, Inc.  (BCDA) 
PDF The decision comes after an assessment of 30-day safety data from subjects who were treated in the trial's low-dose 20 million cell cohort. This data did not show any [Read more]